Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

denileukin diftitox/dexamethasone

Known as: DAB389-IL2/DM 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
INTRODUCTION Denileukin diftitox, a chimeric protein, uses the cytocidal properties of diphtheria toxin to cells expressing… Expand
Is this relevant?
2008
2008
Durable complete remission of mycosis fungoides following erythroderma induced by denileukin diftitox To the Editor: Carretero… Expand
  • figure 1
  • figure 2
  • figure 1
Is this relevant?
Highly Cited
2007
Highly Cited
2007
CD4+CD25+Foxp3+ regulatory T (Treg) cells have been implicated in the lack of effective antitumor immunity. Denileukin diftitox… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2007
2007
Denileukin diftitox (DD; Ontak, Eisai, Woodcliff Lake, NJ) is an FDA-approved targeted therapy for cutaneous T-cell lymphoma… Expand
Is this relevant?
2006
2006
BACKGROUND Denileukin diftitox, a fusion protein consisting of peptide sequences for the enzymatically active and membrane… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Elimination of regulatory T lymphocytes may provide a way to break self-tolerance and unleash the anti-tumor properties of… Expand
Is this relevant?